24 Jul, EOD - Indian

SENSEX 80148.88 (-0.35)

Nifty 50 24413.5 (-0.27)

Nifty Bank 51317 (-0.89)

Nifty IT 40115.05 (0.18)

Nifty Midcap 100 56872.75 (1.04)

Nifty Next 50 71844.65 (0.30)

Nifty Pharma 20908.5 (0.74)

Nifty Smallcap 100 18723.5 (1.76)

24 Jul, EOD - Global

NIKKEI 225 39154.85 (-1.11)

HANG SENG 17311.05 (-0.91)

DOW JONES 39946.51 (-1.02)

S&P 5436.74 (-2.14)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(03 May 2024, 10:22)

Ajanta Pharma spurts as Q4 PAT climbs 66% YoY, board OKs Rs 285-cr share buyback

Ajanta Pharma rallied 9.58% to Rs 2,447.05 after the company’s consolidated net profit surged 65.82% to Rs 202.72 crore on 19.53% rise in revenue from operations to Rs 1,054.08 crore in Q4 FY24 over Q4 FY23.


Profit before tax soared 82.86% to Rs 278.04 crore in Q4 FY24 from Rs 152.05 crore reported in the same period a year ago.

EBITDA in Q4 FY24 was at Rs 278 crore, registering a growth of 86% year on year (YoY). EBITDA margin improved to 26% in the March quarter as compared to17% registered in Q4 FY23.

During the quarter, the company’s revenue from India stood at Rs 326 crore (up 14% YoY), revenue from Asia was at Rs 281 crore ( up 18% YoY), income from Africa stood at Rs 113 crore (up 13% YoY) while revenue from United States was at Rs 261 crore ( up 32% YoY).

Research and development (R&D) expenses were at Rs 50 crore in Q4 FY24, down 20.63% as against Rs 63 crore posted in Q4 FY23.

On full year basis, the company’s consolidated net profit surged 38.81% to Rs 816.17 cr...

More News
More Company News View Company Information